Home › SEC Filings › Press Releases
Press Releases
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| IFRX | PRESS-RELEASE | neutral | 2/10 | InflaRx announced the appointment of Dr. Gabriela Alperovich as SVP & Global Head of Clinical Development, effective Oct | Oct 1, 2026 |
| GENB | PRESS-RELEASE | bullish | 5/10 | Generate Biomedicines announced the first patient dosed in a Phase 1 trial of GB-5267, an AI-designed IL-18 armored CAR | Oct 1, 2026 |
| FATE | PRESS-RELEASE | neutral | 2/10 | Fate Therapeutics announced management participation in Q4 2026 investor conferences. No financial results or material b | Oct 1, 2026 |
| KLRA | PRESS-RELEASE | neutral | 4/10 | Kailera Therapeutics presented Phase 1 data at EASD 2026 showing ribupatide injection is bioequivalent across abdomen, u | Oct 1, 2026 |
| AGMB | PRESS-RELEASE | bullish | 7/10 | Agomab announced positive 48-week open-label extension (OLE) results from the Phase 2a STENOVA trial of ontunisertib in | Oct 1, 2026 |
| REGN | PRESS-RELEASE | bullish | 7/10 | Regeneron and Sanofi expanded their long-standing antibody collaboration, adding four next-generation long-acting antibo | Oct 1, 2026 |
| ADIL | PRESS-RELEASE | neutral | 2/10 | Adial Pharmaceuticals granted a new employee stock option to purchase 155,446 shares at $4.22 as an inducement for hirin | Sep 30, 2026 |
| TEVA | PRESS-RELEASE | neutral | 2/10 | TAPI, a subsidiary of Teva Pharmaceutical Industries, appointed Serge Rogasik as its new CEO. Rogasik brings over 25 yea | Sep 30, 2026 |
| CRVS | PRESS-RELEASE | neutral | 3/10 | Corvus Pharmaceuticals announced the initiation of a Phase 1b trial of soquelitinib for hidradenitis suppurativa, a chro | Sep 30, 2026 |
| GLUE | PRESS-RELEASE | neutral | 5/10 | Monte Rosa Therapeutics announced a conference call and webcast to review clinical results from the GFORCE-1 Phase 1 stu | Sep 30, 2026 |
| CELU | PRESS-RELEASE | neutral | 4/10 | Celularity highlighted progress at Fontaine Vitale, a regenerative medicine center in Bali, Indonesia, expected to open | Sep 30, 2026 |
| QCLS | PRESS-RELEASE | neutral | 3/10 | Q/C Technologies announced a collaboration with Sandia National Laboratories' Center for Integrated Nanotechnologies (CI | Sep 30, 2026 |
| ERNA | PRESS-RELEASE | bullish | 6/10 | Ernexa Therapeutics reported encouraging nonclinical safety results for its lead iPSC-derived cell therapy ERNA-101 acro | Sep 30, 2026 |
| CADL | PRESS-RELEASE | neutral | 4/10 | Candel Therapeutics presented new biomarker data at ASTRO 2026 showing its lead candidate aglatimagene significantly inc | Sep 30, 2026 |
| EPRX | PRESS-RELEASE | bullish | 5/10 | Eupraxia Pharmaceuticals announced updated Phase 1b/2a RESOLVE data for EP-104GI in Eosinophilic Esophagitis, showing lo | Sep 30, 2026 |
| SLXN | PRESS-RELEASE | bearish | 7/10 | Silexion Therapeutics dosed the first patient in its Phase 2/3 trial of SIL204 for locally advanced pancreatic cancer, a | Sep 30, 2026 |
| ABUS | PRESS-RELEASE | neutral | 5/10 | Arbutus Biopharma announced preliminary results of its modified Dutch auction tender offer to repurchase up to $230M of | Sep 30, 2026 |
| WVE | PRESS-RELEASE | bullish | 5/10 | Wave Life Sciences announced that GSK selected a candidate from their research collaboration for a hepatology indication | Sep 30, 2026 |
| MSLE | PRESS-RELEASE | mixed | 6/10 | Satellos Bioscience completed enrollment for BASECAMP, its Phase 2 trial of forazapadin in Duchenne muscular dystrophy, | Sep 30, 2026 |
| RFL | PRESS-RELEASE | mixed | 7/10 | Rafael Holdings announced topline Phase 3 results for Trappsol Cyclo in Niemann-Pick Disease Type C. The primary endpoin | Sep 30, 2026 |
| KLRA | PRESS-RELEASE | neutral | 4/10 | Kailera Therapeutics completed enrollment in its KaiNETIC global Phase 3 program for ribupatide injection (KAI-9531), a | Sep 30, 2026 |
| CNTB | PRESS-RELEASE | bullish | 7/10 | Connect Biopharma reported highly positive Phase 2 topline results for rademikibart in COPD acute exacerbations, showing | Sep 30, 2026 |
| SGMT | PRESS-RELEASE | bearish | 6/10 | Sagimet Biosciences priced an underwritten offering of 8,750,010 shares of Series A common stock at $10.00 per share, pl | Sep 30, 2026 |
| PYXS | PRESS-RELEASE | bearish | 7/10 | Pyxis Oncology priced a public offering of 36M shares and 49.3M common warrants at $2.90/share, raising ~$110M in gross | Sep 30, 2026 |
| EQ | PRESS-RELEASE | neutral | 3/10 | Equillium announced new preclinical data for its EQ504 program, a selective AhR modulator for ulcerative colitis, to be | Sep 29, 2026 |
| DYN | PRESS-RELEASE | bullish | 7/10 | Dyne Therapeutics presented additional one-year efficacy data from the Phase 1/2 ACHIEVE trial of z-basivarsen in DM1 at | Sep 29, 2026 |
| LRMR | PRESS-RELEASE | neutral | 3/10 | Larimar Therapeutics appointed John Harlow as President and COO, effective September 29, 2026, with an inducement grant | Sep 29, 2026 |
| MLYS | PRESS-RELEASE | neutral | 2/10 | Mineralys Therapeutics granted inducement equity awards totaling 81,253 shares (46,430 stock options + 34,823 RSUs) to t | Sep 29, 2026 |
| ARQT | PRESS-RELEASE | neutral | 3/10 | Arcutis Biotherapeutics announced a celebrity endorsement partnership with Simone Biles to launch the 'Skin to Believe I | Sep 29, 2026 |
| MBRX | PRESS-RELEASE | neutral | 6/10 | Moleculin announced completion of Part A enrollment in the pivotal Phase 2/3 MIRACLE trial of Annamycin for R/R AML, wit | Sep 29, 2026 |